Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asfar S Azmi

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
Oncotarget|June 3, 2017
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancerChangwen Ning, Min Liang, Shuang Liu, et al.
Scientific Reports|November 6, 2015
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal TransitionAsfar S Azmi, Irfana Muqbil, Jack Wu, et al.
Advances in Radiation Oncology|December 8, 2022
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation TherapyHusain Yar Khan, Mandana Kamgar, Amro Aboukameel, et al.
Cancers|January 11, 2022
PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell LymphomaHusain Yar Khan, Md Hafiz Uddin, Suresh Kumar Balasubramanian, et al.
Oncotarget|May 31, 2011
Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumorsAsfar S Azmi, Sanjeev Banerjee, Shadan Ali, et al.
Oncotarget|November 20, 2018
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progressionAmro Aboukameel, Irfana Muqbil, Erkan Baloglu, et al.
Oncotarget|October 8, 2016
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell deathTrinayan Kashyap, Christian Argueta, Amro Aboukameel, et al.
Plos One|June 16, 2011
Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathwaysZhiwei Wang, Sanjeev Banerjee, Aamir Ahmad, et al.
Cancer Metastasis Reviews|October 6, 2021
Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technologyWilliam A Hall, Mandana Kamgar, Beth A Erickson, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axisSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Oncotarget|June 3, 2017
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancerChangwen Ning, Min Liang, Shuang Liu, et al.
Scientific Reports|November 6, 2015
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal TransitionAsfar S Azmi, Irfana Muqbil, Jack Wu, et al.
Advances in Radiation Oncology|December 8, 2022
Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation TherapyHusain Yar Khan, Mandana Kamgar, Amro Aboukameel, et al.
Cancers|January 11, 2022
PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell LymphomaHusain Yar Khan, Md Hafiz Uddin, Suresh Kumar Balasubramanian, et al.
Oncotarget|May 31, 2011
Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumorsAsfar S Azmi, Sanjeev Banerjee, Shadan Ali, et al.
Oncotarget|November 20, 2018
Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progressionAmro Aboukameel, Irfana Muqbil, Erkan Baloglu, et al.
Oncotarget|October 8, 2016
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell deathTrinayan Kashyap, Christian Argueta, Amro Aboukameel, et al.
Plos One|June 16, 2011
Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathwaysZhiwei Wang, Sanjeev Banerjee, Aamir Ahmad, et al.
Cancer Metastasis Reviews|October 6, 2021
Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technologyWilliam A Hall, Mandana Kamgar, Beth A Erickson, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axisSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.
Pageof 16